- Home
- WFG vs LGND Comparison
WFG vs LGND Comparison
Compare WFG & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WFG | LGND |
|---|---|---|
| Founded | 1955 | 1987 |
| Country | Canada | United States |
| Employees | N/A | 68 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 3.9B |
| IPO Year | N/A | 1992 |
Fundamental Metrics
Financial Performance| Metric | WFG | LGND |
|---|---|---|
| Price | $60.19 | $188.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $93.00 | ★ $144.71 |
| AVG Volume (30 Days) | ★ 275.7K | 139.7K |
| Earning Date | 10-22-2025 | 08-05-2025 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,702,000,000.00 | $181,488,000.00 |
| Revenue This Year | N/A | $18.41 |
| Revenue Next Year | $9.45 | $18.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 53.40 |
| 52 Week Low | $57.34 | $81.74 |
| 52 Week High | $94.18 | $129.90 |
Technical Indicators
Market Signals| Indicator | WFG | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 45.49 | 45.58 |
| Support Level | $59.21 | $179.65 |
| Resistance Level | $63.02 | $192.44 |
| Average True Range (ATR) | 1.53 | 6.57 |
| MACD | 0.24 | -2.06 |
| Stochastic Oscillator | 37.15 | 31.70 |
Price Performance
Historical ComparisonAbout WFG West Fraser Timber Co. Ltd.
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is one of the largest oriented strand board producers in the world.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.